| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
The primary action of (+)-Oxypeucedanin methanolate is the inhibition of Prostaglandin E2 (PGE2) production. By inhibiting PGE2 synthesis, it indirectly modulates downstream signaling pathways, including the EP receptors. The specific molecular target has not been fully elucidated, but it is hypothesized to affect the cyclooxygenase (COX) enzymes, which are key enzymes in the prostaglandin synthesis pathway.
|
|---|---|
| ln Vitro |
(+)-Oxypeucedanin methanolate inhibits prostaglandin E2 production. As a naturally occurring compound, it exhibits an inhibitory effect on PGE2 synthesis. The specific IC50 value for PGE2 inhibition has not been provided in standard chemical databases. It is hypothesized to act via modulation of the COX-2 enzyme.
|
| ln Vivo |
Specific in vivo activity data for (+)-Oxypeucedanin methanolate has not been published. Given its ability to inhibit PGE2 production in vitro, it is expected to show anti-inflammatory effects in standard animal models (e.g., carrageenan-induced paw edema) where PGE2 is a key mediator of inflammation and pain.
|
| Enzyme Assay |
The specific protocol for measuring PGE2 inhibition is well-established. In this protocol, LPS-stimulated RAW 264.7 macrophages (or a similar cell line) are cultured and treated with (+)-Oxypeucedanin methanolate. The control wells receive vehicle (e.g., DMSO) and are stimulated with LPS. Positive control wells may receive a standard COX inhibitor like indomethacin. After an overnight incubation, the cell culture supernatant is collected, and the concentration of PGE2 is quantified using a commercial competitive ELISA kit (Enzyme-Linked Immunosorbent Assay).
|
| Cell Assay |
For in vitro assays, RAW 264.7 murine macrophages are seeded in 24-well plates. The cells are pre-treated with various concentrations of (+)-Oxypeucedanin methanolate (e.g., 1, 5, 10, 25, 50 ug/mL) for 1 hour. Then, Lipopolysaccharide (LPS) is added to a final concentration of 1 ug/mL to induce inflammation, except for the negative control wells. After 18-24 hours of incubation, the supernatant is collected for PGE2 ELISA measurement, and cell viability is assessed using an MTT assay to ensure the inhibitory effect is not due to cytotoxicity.
|
| Animal Protocol |
There are no specific published protocols for the in vivo use of (+)-Oxypeucedanin methanolate. A generalized protocol for testing PGE2 inhibition in vivo would involve a carrageenan-induced paw edema model in rats (200 g). Test compound would be administered orally (50-200 mg/kg) or intraperitoneally 1 hour prior to a subplantar injection of 1% carrageenan. Paw volume would be measured at 0, 1, 3, 5, and 24 hours. Exudate from the paw could be collected to measure PGE2 levels by ELISA.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic data for (+)-Oxypeucedanin methanolate has not been published. As a natural product furanocoumarin, its ADME properties would be of interest to researchers. Furanocoumarins are generally known to be metabolized by cytochrome P450 enzymes (CYP3A4). Some furanocoumarins are mechanism-based inhibitors of CYP3A4, which could lead to drug-drug interactions. Bioavailability may be limited by first-pass metabolism.
|
| Toxicity/Toxicokinetics |
Toxicity data for (+)-Oxypeucedanin methanolate is not available in standard databases. As a natural product, potential toxicity is likely to be low, but furanocoumarins are known to be phototoxic and photosensitizing agents. Therefore, handling this compound would require protection from UV light. Standard research safety for natural products includes testing for genotoxicity (Ames test) and cytotoxicity at high concentrations.
|
| References | |
| Additional Infomation |
According to reports, Japanese angelica and hairy chrysanthemum contain (+)-4-[(R)-2-hydroxy-3-methoxy-3-methylbutoxy]-7H-furano[3,2-g][1]benzopyran-7-one, and there is relevant data.
(+)-Oxypeucedanin methanolate is exclusively a research chemical and has no clinical approval. Its significance lies in its natural origin and its role in explaining the anti-inflammatory activity of traditional medicinal herbs. It serves as a tool compound for studying the mechanisms of PGE2 regulation, potentially offering a structural framework for developing new non-steroidal anti-inflammatory drugs (NSAIDs). Methanolate refers to the crystalline form of the compound. |
| Molecular Formula |
C17H18O6
|
|---|---|
| Molecular Weight |
318.32
|
| Exact Mass |
318.11
|
| CAS # |
52939-12-5
|
| PubChem CID |
15945061
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.300±0.06 g/cm3
|
| Boiling Point |
504.3±50.0 °C
|
| LogP |
2.703
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
23
|
| Complexity |
474
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC(C)([C@@H](COC1=C2C=CC(=O)OC2=CC3=C1C=CO3)O)OC
|
| InChi Key |
UHENVVIVPZCJOA-CQSZACIVSA-N
|
| InChi Code |
InChI=1S/C17H18O6/c1-17(2,20-3)14(18)9-22-16-10-4-5-15(19)23-13(10)8-12-11(16)6-7-21-12/h4-8,14,18H,9H2,1-3H3/t14-/m1/s1
|
| Chemical Name |
4-[(2R)-2-hydroxy-3-methoxy-3-methylbutoxy]furo[3,2-g]chromen-7-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1415 mL | 15.7075 mL | 31.4149 mL | |
| 5 mM | 0.6283 mL | 3.1415 mL | 6.2830 mL | |
| 10 mM | 0.3141 mL | 1.5707 mL | 3.1415 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
